Biotech IPO & Funding Landscape 2026: The Window Is Wide Open
After four lean years from 2022 to 2025, biotech capital markets have roared back: 22 IPOs raised $7.5 billion through Q3 2026. AI platforms and China-sourced assets are among the new listings. Here’s the complete picture.
The Capital Markets Are Back
In the first week of February 2026, Veradermics, Eikon, Agomab, and SpyGlass raised nearly $1 billion through IPOs in three days. Eikon Therapeutics led with a $381 million offering, briefly the largest biotech IPO in two years, before six larger 2026 IPOs, led by Parabilis ($670M) and Kailera ($625M) in base offering size, overtook it. By the end of Q3 2026, 22 biopharma IPOs had raised $7.5 billion, more than in any full year from 2022 to 2025. For biotech companies and their investors, understanding the new rules of the capital markets game is critical.
The IPO Market Recovery
The biotech IPO market has undergone a remarkable transformation. After the devastating 2022-2023 drought—when rising interest rates, biotech stock selloffs, and risk aversion effectively shut the IPO window—activity improved in 2024 (19 offerings, $3.8 billion), slumped again in 2025 to its least active year in over a decade (9 offerings, $1.6 billion), and then reopened sharply in early 2026 (J.P. Morgan).
Biotech IPO Market: Recovery at a Glance
The recovery has been driven by several converging factors. The XBI (SPDR S&P Biotech ETF) rebounded from its 2022 lows, giving investors confidence that public biotech equities could once again generate returns. The Federal Reserve’s easing that began in September 2024 reduced the discount rate applied to long-duration biotech assets, though the Fed reversed course with a 0.25-point rate increase in September 2026. And a wave of successful M&A exits in 2025 — analyzed in our biotech M&A trends and patent cliff guide — reminded the market that biotech innovation could command premium acquisition multiples.
Perhaps most importantly, the quality of companies approaching the public markets has improved dramatically. Unlike the 2021 boom, when pre-clinical and even platform-stage companies could IPO, the 2025-2026 class is dominated by clinical-stage companies: 11 of the 13 biopharma IPOs in H1 2026 had Phase II or later assets (J.P. Morgan), most with differentiated mechanisms and clear paths to commercialization or partnership.
The Quality Filter
Top Biotech IPOs of 2025-2026
The most notable biotech IPOs reflect the market's appetite for differentiated science across therapeutic areas—from AI-powered drug discovery to radiopharmaceuticals and CNS disorders.
Largest Biotech IPOs, 2025-2026
| Company | Raised | Focus Area | Date | Notable |
|---|---|---|---|---|
| Parabilis Medicines | $670M | Oncology | Jun 2026 | Largest biotech IPO of 2026 to date |
| Kailera Therapeutics | $625M | Obesity | Apr 2026 | Pipeline in-licensed from Hengrui |
| ADARx Pharmaceuticals | $446M | RNA therapeutics | Sep 2026 | Largest Q3 2026 offering |
| Generate:Biomedicines | $400M | AI protein design | Feb 2026 | Lead antibody in Phase 3 |
| Kardigan | $400M | Cardiovascular | Jun 2026 | Precision cardiovascular medicines |
| Braveheart Bio | $383M | Cardiovascular | Aug 2026 | Cardiac myosin inhibitor in-licensed from Hengrui |
| Eikon Therapeutics | $381M | Oncology | Feb 2026 | Upsized; super-resolution imaging platform |
| Electra Therapeutics | $350M | Immunology | Sep 2026 | SIRP-targeted immune cell depletion |
| Latigo Biotherapeutics | $346M | Pain | Aug 2026 | Non-opioid oral Nav1.8 inhibitors |
| Aktis Oncology | $318M | Radiopharmaceuticals | Jan 2026 | First biotech IPO of 2026 |
| Hemab Therapeutics | $302M | Hematology | Apr 2026 | Bispecific antibody for rare bleeding disorders |
| Avalyn Pharma | $300M | Respiratory | Apr 2026 | Inhaled therapies for pulmonary fibrosis |
| Attovia Therapeutics | $289M | Immunology | Aug 2026 | Lead biologic ATTO-1310 targets IL-31 |
| LB Pharmaceuticals | $285M | Neuroscience | Sep 2025 | Largest biotech IPO of 2025 |
| Odyssey Therapeutics | $279M | Immunology | May 2026 | Oral RIPK2 scaffolding inhibitor |
The 15 largest biopharma (drug developer) IPOs on Nasdaq and the NYSE since January 2025, ranked by base offering size (before the underwriters’ option to buy additional shares). Source: each company’s final prospectus on SEC EDGAR.
Eikon Therapeutics: The Breakout IPO
Eikon Therapeutics’ $381 million IPO in February 2026 was an early marker of the recovery. Co-founded by Nobel laureate Eric Betzig and Robert Tjian and led by Roger Perlmutter, Eikon uses super-resolution single-molecule tracking to follow individual protein movements inside living cells in real time. Its initial focus is oncology, with a clinical pipeline that includes in-licensed programs alongside platform-derived ones.
Eikon’s IPO drew demand through a combination of a differentiated technology platform, multiple clinical-stage programs, and a strong syndicate of private investors (including The Column Group, Lux, and Foresite). The offering was upsized, but the shares later traded below the IPO price, a reminder that a big book does not guarantee aftermarket support.
Aktis Oncology: Riding the Radiopharmaceutical Wave
Aktis Oncology's $318 million IPO in January 2026 marked the first biotech IPO of the year and capitalized on the radiopharmaceutical investment theme. With the global radiopharmaceuticals market projected to exceed $26 billion in sales by 2032, Aktis’s miniprotein radioconjugate platform attracted significant investor interest. Its 2024 collaboration with Eli Lilly ($60 million upfront plus an equity investment, with up to $1.2 billion in milestones) provided critical de-risking.
The February 2026 Surge
Venture Funding Trends
Behind the IPO recovery lies a steady venture funding base: biopharma companies raised $30.5 billion in 2025 and $23.9 billion in the first three quarters of 2026, although funding slowed in Q3 (J.P. Morgan). For companies considering alternatives to the public markets, our NewCo formation services help structure asset-centric spinouts backed by venture capital. Biotech venture capital has evolved significantly since the 2021-2022 correction, with investors demanding more discipline and de-risking before committing capital.
Series A: The New Bar
Early-stage rounds remain disciplined: J.P. Morgan puts the 2026 median venture round (all round types) at $23 million for platform companies, $26 million for preclinical companies, and $38 million for Phase I companies. Investors now expect IND-enabling data or early clinical signals before committing. Pure platform stories without clinical validation struggle to raise.
Series B/C: Crossover Capital
Late-stage private rounds have become larger and more competitive. Crossover investors—hedge funds and public market investors participating in private rounds—are back in force in pre-IPO rounds.
Mega-Rounds Returning
Large venture rounds are back: 68 of the 385 biopharma rounds in the first three quarters of 2026 raised $100 million or more (J.P. Morgan), particularly for AI drug discovery platforms and companies with validated clinical data. These mega-rounds often include sovereign wealth funds and corporate venture arms alongside traditional biotech VCs.
Geographic Diversification
While the US remains the dominant biotech venture market, Europe is a clear second, led by the UK, its largest hub, and Switzerland (J.P. Morgan). China’s biotech sector shows its weight mainly through licensing deals with global pharma rather than venture rounds.
Venture Investors Behind the 2025-2026 IPO Class
Specialist investors that kept funding companies through the downcycle are now seeing exits through the recovery. The prospectuses of the 2025-2026 IPO class show which investors backed the new listings:
| Firm | Strategy | Notable Recent Investments |
|---|---|---|
| The Column Group / Lux Capital / Foresite | Early stage to growth | Eikon Therapeutics (Series A and A-1 investors) |
| Flagship Pioneering | Company creation | Generate:Biomedicines (IPO February 2026) |
| MPM BioImpact / Vida Ventures / EcoR1 | Early stage to crossover | Aktis Oncology |
| RA Capital Management | Crossover specialist | Aktis Oncology pre-IPO round |
| Viking Global / Surveyor Capital (Citadel) | Crossover | Veradermics |
| Deep Track / TCG Crossover / Vida Ventures | Crossover | LB Pharmaceuticals |
The Venture-to-IPO Pipeline
AI Drug Discovery Goes Public
One of the most significant developments in the 2025-2026 biotech capital markets is the arrival of AI- and data-driven drug discovery companies on the public markets. Generate:Biomedicines designs protein therapeutics with generative AI; Eikon combines super-resolution imaging of proteins in living cells with its own AI and machine-learning algorithms, alongside in-licensed clinical programs; and Iambic Therapeutics followed in October 2026. Their pitch is that machine learning, computational biology, and large-scale data sit at the core of discovery rather than at its edges.
Eikon Therapeutics — IPO: $381M (Feb 2026)
Eikon's platform uses super-resolution fluorescence microscopy to visualize individual protein movements inside living cells. This resolution enables the identification of drug targets and mechanisms that are invisible to conventional approaches. Its initial focus is oncology, with discovery research in oncology and neurologic disease.
Generate:Biomedicines — IPO: $400M (Feb 2026)
A Flagship Pioneering company, Generate:Biomedicines has developed a generative AI platform for designing novel protein therapeutics—particularly antibodies. Its lead antibody, GB-0895 (anti-TSLP), is in Phase 3 trials for severe asthma, and it partners with Amgen and Novartis. The approach could compress the timeline from target identification to clinical candidate.
Do AI Biotechs Command Premium Valuations?
AI-driven drug discovery companies pitch three advantages to IPO investors. First, their platforms can generate multiple programs simultaneously, creating built-in pipeline diversification that reduces single-asset risk. Second, the speed of their discovery engines suggests shorter timelines to clinical milestones. Third, partnerships with major pharma companies (such as Generate’s collaborations with Amgen and Novartis) provide both validation and non-dilutive funding. The market has not yet granted a clear premium, though: Generate closed 21% below its IPO price on its first day, and Eikon traded below its offering price in the weeks after listing.
However, skepticism remains warranted. The AI drug discovery thesis has yet to produce a blockbuster approved drug. Most AI-discovered molecules are still in early clinical stages. Any premium valuation bakes in the expectation that these platforms will fundamentally outperform traditional approaches—a thesis that will be tested as clinical data matures through 2026-2027. For a deeper read on the platforms going public, see our AI drug discovery companies power list.
The AI Valuation Premium
The SPAC Reckoning
The biotech SPAC (Special Purpose Acquisition Company) boom of 2020-2021 is now widely regarded as one of the most destructive episodes in modern biotech finance. The aftermath continues to ripple through the market in 2026.
SPACs and Reverse Mergers by the Numbers
The biotech SPAC model failed for fundamental reasons. Pre-clinical and early-stage companies that went public through SPACs bypassed the rigorous due diligence of the traditional IPO process. Many had no clinical data, no revenue, and limited management experience operating public companies. The SPAC structure—with its dilutive warrants, sponsor promotes, and short-fuse redemption dynamics—was poorly suited to drug development timelines that span years.
Many SPAC-merged biotechs went on to trade far below their listing prices, conduct reverse stock splits, or delist. The lesson was clear: there are no shortcuts in drug development, and the public markets are unforgiving of companies that arrive without clinical proof-of-concept and the infrastructure to operate as public entities. The route has not disappeared, though: BridgeBio Oncology Therapeutics raised about $381.8 million when it closed its merger with Helix Acquisition Corp. II in 2025, and specialist investors launched new life-sciences SPACs in 2026.
What Replaced SPACs
The capital that once flowed into SPACs has been redirected into three channels: larger traditional IPOs with stronger syndicate support, private crossover rounds that keep companies private longer, and structured strategic deals (licensing deals, option-to-acquire structures, and earn-out arrangements). The rise of VC-backed NewCo formation models has also emerged as an attractive alternative to the public markets for early-stage assets, and reverse mergers have rebounded (27 through Q3 2026, against 12 in all of 2025, according to J.P. Morgan). The traditional IPO has reasserted itself as the gold standard for biotech public market entry, with the added benefit that the 2022-2023 correction raised the quality bar significantly.
Secondary Offerings & Follow-On Financing
While IPOs capture headlines, the secondary offering market has been equally active—and in many ways more important for the broader biotech ecosystem. Follow-on financings enable already-public biotechs to fund clinical programs, extend runways, and capitalize on positive data readouts.
At-the-Market (ATM) Offerings
ATM programs have become the preferred method for small and mid-cap biotechs to raise incremental capital. These allow companies to sell shares gradually into the market at prevailing prices, avoiding the dilution shock of a large secondary.
Bought Deal Follow-Ons
For biotechs with positive clinical catalysts, bought deal follow-ons—where an investment banking underwriter purchases the entire offering and resells to investors—have enabled rapid capital raises of $200-500 million within days of positive data releases. This speed-to-market is critical for companies looking to capitalize on stock price momentum.
Convertible Notes
Convertible notes let larger biotechs raise capital with less dilution than equity (through conversion premiums) while giving investors downside protection. Debt remains a small part of biotech funding, though: nonbank debt issuance totaled $1.9 billion in 2025, against $1.6 billion in 2024 (Young & Partners).
Biotech Equity Financing in 2025
Crossover Investor Trends
Crossover investors—institutional investors who participate in both private venture rounds and public market investments—have become the single most important force in biotech capital formation. Their participation in a pre-IPO round is now effectively a prerequisite for a successful biotech IPO.
Why Crossover Rounds Matter
Price Discovery
Crossover rounds establish a pre-IPO valuation that anchors the IPO pricing range. Companies that attract top crossover investors at strong valuations signal quality to the broader public market, reducing IPO pricing risk.
Anchor Orders
Crossover investors typically commit to purchasing a significant portion of the IPO allocation, providing demand certainty for the underwriting syndicate. A "warm" book with 2-3 anchor crossover orders can mean the difference between pricing above range and pulling the offering.
Post-IPO Support
Unlike pure venture investors who may sell at or shortly after IPO, sophisticated crossover investors often hold and add to positions over 12-24 months. This provides stock price stability during the critical post-IPO period when companies need to execute on clinical milestones.
Validation Signal
When firms like RA Capital, Perceptive Advisors, Baker Brothers, or Fidelity participate in a crossover round, it sends a powerful signal to the market. These firms conduct deep scientific due diligence, and their participation is treated as an endorsement of the company's science and commercial potential.
The Crossover Landscape in 2026
The crossover investor base has expanded significantly since 2021. Traditional biotech crossover specialists like RA Capital and Perceptive Advisors have been joined by generalist hedge funds (Viking, Citadel), sovereign wealth funds (GIC, Temasek, Mubadala), and large asset managers (Fidelity, T. Rowe Price, BlackRock) that have built dedicated life sciences teams. This expanded investor base has increased the total capital available for biotech crossover rounds, supporting larger IPO sizes.
The Crossover Premium
What Makes a Successful Biotech IPO in 2026
The 2025-2026 IPO class has established a clear playbook for what the market rewards. Companies considering an IPO should measure themselves against these criteria:
Clinical Proof-of-Concept
The single most important factor. Companies with Phase 2 data demonstrating efficacy in their lead indication tend to achieve higher valuations. The 2021 era of pre-clinical IPOs is over: most investors now look for at least Phase 1b/2a data showing a clear signal of activity, and 11 of the 13 biopharma IPOs in H1 2026 had Phase II or later assets (J.P. Morgan).
Differentiated Mechanism of Action
"Me-too" assets struggle to attract IPO investors. Many 2025-2026 IPOs led with a differentiated approach: Eikon's super-resolution imaging platform, Aktis's miniprotein radioconjugates, and MapLight’s M1/M4 muscarinic agonist for schizophrenia, co-formulated to limit the peripheral side effects of its drug class. Investors will pay for genuinely new science, but demand evidence that novelty translates to clinical benefit.
Strong Crossover Round
As discussed above, a successful crossover round with recognized investors is effectively a prerequisite. Companies should target 3-5 top-tier crossover investors and ensure the round is structured to demonstrate valuation progression from earlier venture rounds.
Management Team with Public Company Experience
Investors want to see a CEO and CFO who have operated public biotech companies before. The post-IPO environment demands quarterly earnings calls, SEC compliance, investor relations, and the ability to navigate stock price volatility around clinical data readouts. Companies that lack experienced public company leadership should recruit it before the IPO roadshow.
Clear Path to Value-Creating Milestones
IPO investors need a narrative that connects the capital raised to specific catalysts: pivotal trial initiations, data readouts, regulatory milestones, or partnership announcements. The most successful S-1 filings present a clear timeline of 12-24 month catalysts that will drive stock re-rating. An IPO raise should fund the company through at least 2 major inflection points.
Robust IP Protection
Thorough intellectual property protection—including composition of matter patents, method of use claims, and a clear freedom-to-operate analysis—is essential. Investors conduct detailed patent due diligence, and companies with weak or narrow IP face meaningful valuation discounts relative to peers with strong patent portfolios.
The $250M+ IPO Threshold
Outlook: Capital Markets Ahead
The biotech capital markets outlook for the remainder of 2026 is cautiously optimistic. The fundamental drivers of the recovery remain intact: a deep pipeline of well-funded private companies, sustained M&A activity creating exit opportunities, and institutional investor reengagement with the sector.
IPO Pipeline
IPOs have run at roughly two to three a month in 2026: 13 in H1 and nine more in Q3. A steady flow of filings suggests activity can continue if market conditions remain favorable.
Sector Rotation Risk
The biggest risk to the IPO window is a broader sector rotation away from healthcare. If technology or energy stocks dramatically outperform, institutional allocators may reduce biotech exposure, tightening the IPO window.
Interest Rate Sensitivity
Biotech stocks—as long-duration assets—remain sensitive to interest rate movements. The Fed’s 0.25-point rate increase in September 2026 is a reminder that further tightening could pressure valuations and slow IPO activity.
M&A Exit Cycle
With biopharma M&A already at $138.9 billion of upfront value across 113 deals through Q3 2026, above full-year 2025’s $122.1 billion (J.P. Morgan), acquisitions of recently listed companies will keep encouraging venture-backed biotechs to go public, creating a virtuous cycle.
China-to-US IPOs
China-sourced assets are reaching US public markets mainly through NewCos rather than direct listings: Kailera ($625 million IPO) in-licensed its pipeline from Hengrui, and Braveheart Bio ($383 million) in-licensed its lead cardiac myosin inhibitor from Hengrui too. Chinese companies themselves have favored Hong Kong, where 14 pre-revenue biotechs listed under Chapter 18A in 2025.
AI Drug Discovery Wave
Following Eikon and Generate:Biomedicines, Iambic Therapeutics ($150 million, October 2026) became the latest AI-driven drug developer to list. This category will keep testing investor appetite for platform premiums versus clinical-stage traditional biotechs.
For companies planning an IPO, the message is clear: the window is open, but it rewards preparation and quality. Companies with clinical proof-of-concept, strong crossover investor support, experienced management, and a clear value-creation narrative will find a receptive market. Companies that try to shortcut the process—as the SPAC era demonstrated—will be punished.
At Vision Lifesciences, we work with biotech companies and their investors to navigate the strategic decisions that surround capital markets events. Whether you are a private biotech exploring partnership options as an alternative or complement to an IPO, or a pharma company evaluating acquisition targets among the newly public class, understanding the capital markets landscape is essential to making informed deal decisions.
Frequently Asked Questions
How is the biotech IPO market performing in 2026?
Biopharma IPOs on Nasdaq and the NYSE raised $7.5 billion across 22 offerings through Q3 2026, more than in any full year from 2022 through 2025 (J.P. Morgan). The largest so far by base offering size are Parabilis Medicines ($670M) and Kailera Therapeutics ($625M). It is a sharp turnaround from 2025, the least active IPO year in over a decade, with just 9 offerings and $1.6 billion raised.
What are the largest biotech IPOs in 2025-2026?
The largest biotech IPOs of 2026 so far are Parabilis Medicines ($670M), Kailera Therapeutics ($625M), ADARx Pharmaceuticals ($446M), Generate:Biomedicines and Kardigan ($400M each), and Braveheart Bio ($383M), based on base offering size. In 2025 the largest were LB Pharmaceuticals ($285M), Metsera ($275M), and MapLight Therapeutics ($251M).
Are AI drug discovery companies going public?
Yes. Eikon Therapeutics raised $381 million in February 2026, Generate:Biomedicines $400 million weeks later, and Iambic Therapeutics $150 million in October 2026. Valuations have been tested: Generate closed 21% below its IPO price on its first day, and Eikon traded below its offering price in the weeks after listing.
What makes a successful biotech IPO in 2026?
Successful biotech IPOs in 2026 share several characteristics: differentiated science with clear clinical proof-of-concept, a strong crossover round with top-tier investors, experienced management teams, a clear commercial path, robust IP protection, and ideally Phase 2 or later clinical data. Many of the $250M+ IPOs were multi-asset stories, but not all: Veradermics raised $256 million on a single lead candidate.
What happened to biotech SPACs?
The 2020-21 biotech SPAC boom ended badly for many companies, but the route has not disappeared. BridgeBio Oncology Therapeutics raised about $381.8 million when it closed its merger with Helix Acquisition Corp. II in 2025, and specialist investors launched new life-sciences SPACs in 2026, including TCGX Acquisition Corp. II and Frazier Life Sciences Acquisition Corp. II. Reverse mergers have also rebounded, with 27 through Q3 2026 against 12 in all of 2025 (J.P. Morgan).
Sources
- Vision Lifesciences research: our own deal tracking and insights from our day-to-day cross-border licensing and M&A advisory work (about us)
- J.P. Morgan, Q3 2026 Biopharma Licensing and Venture Report (DealForma data: IPOs, venture, M&A, reverse mergers)
- J.P. Morgan, Q2 2026 Biopharma Licensing and Venture Report (H1 2026 IPOs; Kailera and Parabilis IPOs)
- J.P. Morgan, Q4 2025 Biopharma Licensing and Venture Report (2025 IPOs the least active in over a decade)
- Eikon Therapeutics, IPO prospectus (February 2026)
- Eikon Therapeutics, preliminary prospectus (January 2026; 17,648,000 shares before the offering was upsized)
- Veradermics, IPO prospectus (February 2026)
- Agomab Therapeutics, IPO prospectus (February 2026)
- SpyGlass Pharma, IPO prospectus (February 2026)
- Aktis Oncology, IPO prospectus (January 2026)
- Generate:Biomedicines, IPO prospectus (February 2026)
- Kailera Therapeutics, IPO prospectus (April 2026)
- Parabilis Medicines, IPO prospectus (June 2026)
- Kardigan, IPO prospectus (June 2026)
- ADARx Pharmaceuticals, IPO prospectus (September 2026)
- Braveheart Bio, IPO prospectus (August 2026)
- Electra Therapeutics, IPO prospectus (September 2026)
- Latigo Biotherapeutics, IPO prospectus (August 2026)
- Hemab Therapeutics, IPO prospectus (April 2026)
- Avalyn Pharma, IPO prospectus (April 2026)
- Attovia Therapeutics, IPO prospectus (August 2026)
- Odyssey Therapeutics, IPO prospectus (May 2026)
- Metsera, IPO prospectus (January 2025)
- Iambic Therapeutics, IPO prospectus (October 2026)
- LB Pharmaceuticals, IPO prospectus (September 2025)
- MapLight Therapeutics, IPO prospectus (October 2025)
- GEN, AI drug developer Generate’s $400M IPO (first-day trading; Eikon after listing)
- BridgeBio Oncology Therapeutics, closing of business combination with Helix Acquisition Corp. II (2025)
- Frazier Life Sciences Acquisition Corp. II, IPO prospectus (October 2026)
- TCGX Acquisition Corp. II, IPO prospectus (October 2026)
- Young & Partners, biotech equity and debt financing in 2025 (Pharmaceutical Executive, March 2026)
- Federal Reserve, FOMC statement (September 16, 2026)
- Federal Reserve, FOMC statement (September 18, 2024; first rate cut of the easing cycle)
- finews.asia, Hong Kong reclaims global IPO crown (Chapter 18A listings in 2025)